Item

Primary analysis of the EORTC-2139-MG/Columbus-AD trial: a randomized trial of adjuvant encorafenib and binimetinib versus placebo in high-risk stage II melanoma with a BRAF-V600E/K mutation

Christopher, A.
; 
Akkooi, J. V.
; 
Mandala, M.
; 
Kicinski, M.
; 
Govaerts, A. S.
; 
Hauschild, A.
; 
Rutkowski, P.
; 
Arenberger, P.
; 
Ascierto, P. A.
; 
Tomczak, P.
... show 10 more
Citations
Google Scholar:
Lookup
Altmetric:
Abstract
Authors
Christopher, A.
Akkooi, J. V.
Mandala, M.
Kicinski, M.
Govaerts, A. S.
Hauschild, A.
Rutkowski, P.
Arenberger, P.
Ascierto, P. A.
Tomczak, P.
Quereux, G.
De Galitiis, F.
Dutriaux, C.
Gebhardt, C.
Kapiteijn, E.
Machet, L.
Klauck, I.
Sansas, B.
Lorigan, P.
Long, G. V.
Eggermont, A. M.
Affiliation
Univ Sydney, Melanoma Inst Australia, Sydney, NSW, Australia Univ Perugia, St Maria Misericordia Hosp, Dept Med Oncol, Perugia, Italy EORTC Headquarters, Brussels, Belgium Univ Hosp UKSH, Dept Dermatol, Kiel, Germany Maria Sklodowska Curie Natl Inst Oncol Ctr, Warsaw, Poland Univ Hosp Kralovske Vinohrady, Prague, Czech Republic Charles Univ Third Med Fac, Prague, Czech Republic Ist Nazl Tumori IRCCS Fdn G Pascale, Naples, Italy Nantes Univ Hosp, Pratia Poznan Med Ctr, Skin Canc Unit, Poznan, Nantes, France Ist Dermopat immacolata, Med Oncol, Rome, Italy Hop St Andre, CHU Bordeaux, Bordeaux, France Univ Med Ctr Hosp Hamburg Eppendorf, Skin Canc Ctr, Dept Dermatol, Hamburg, Germany Leiden Univ Med Ctr, Dept Med Oncol, Leiden, Netherlands CHU Tours Hosp Trousseau, Tours, France Pierre Fabre Medicament, Boulogne Billancourt, France Pierre Fabre, Toulouse, France Univ Manchester, Manchester, England Christie NHS Fdn Trust, Manchester, England Univ Sydney, Melanoma Inst Australia, Fac Med & Hlth, Sydney, NSW, Australia Mater & Royal North Shore Hosp, Sydney, NSW, Australia Univ Med Ctr, Fac Med, Utrecht, Netherlands Princess Maxima Ctr, Utrecht, Netherlands Comprehens Canc Ctr Munich, Munich, Germany Tech Univ Munich, Munich, Germany Ludwig Maximilians Univ Munchen, Munich, Germany
Description
Date
2025
Publisher
Collections
All Christie Publications
Show all metadata
Keywords
Type
Meetings and Proceedings
Citation
Christopher A, Akkooi JV, Mandala M, Kicinski M, Govaerts AS, Hauschild A, et al. Primary analysis of the EORTC-2139-MG/Columbus-AD trial: A randomized trial of adjuvant encorafenib and binimetinib versus placebo in high-risk stage II melanoma with a BRAF-V600E/K mutation. JOURNAL OF CLINICAL ONCOLOGY. 2025 JUN 10;43(17_SUPPL):LBA9501-LBA. PubMed PMID: WOS:001511753700001. English.
Journal Title
Journal ISSN
Volume Title
URI
https://christie.openrepository.com/handle/10541/628011
Embedded videos